Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei

Table 2 Adverse events, n (%)

Adverse events	Total	Grade 1-2	Grade 3-5
Total	24 (75.0)	20 (62.5)	5 (15.6)
Neutropenia	14 (43.8)	12 (37.5)	2 (6.3)
Thrombocytopenia	1 (3.1)	1 (3.1)	0 (0)
Anemia	16 (50.0)	12 (37.5)	4 (12.5)
Peripheral neurotoxicity	8 (25.0)	6 (18.8)	2 (6.3)
Fatigue	9 (28.1)	9 (28.1)	0 (0)
Nausea and vomiting	15 (46.9)	14 (43.8)	1 (3.1)
Liver damage	7 (21.9)	7 (21.9)	0 (0)
Renal impairment	9 (28.1)	9 (28.1)	0 (0)
Proteinuria	5 (15.6)	4 (12.5)	1 (3.1)
Hypertension	5 (15.6)	5 (15.6)	0 (0)
Allergy	1 (3.1)	1 (3.1)	0 (0)